The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Zenith Capital's quick ratio for the quarter that ended in Jan. 2024 was 0.52.
Zenith Capital has a quick ratio of 0.52. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Zenith Capital's Quick Ratio or its related term are showing as below:
TSXV:ZENI.P'
s Quick Ratio Range Over the Past 10 Years
Min: 0.05 Med: 0.17 Max: 1.04
Current: 0.52
During the past 6 years, Zenith Capital's highest Quick Ratio was 1.04. The lowest was 0.05. And the median was 0.17.
TSXV:ZENI.P's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.6
vs TSXV:ZENI.P: 0.52
Zenith Capital Quick Ratio Historical Data
The historical data trend for Zenith Capital's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zenith Capital's Quick Ratio
For the Biotechnology subindustry, Zenith Capital's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenith Capital's Quick Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zenith Capital's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Zenith Capital's Quick Ratio falls into.
Zenith Capital Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Zenith Capital's Quick Ratio for the fiscal year that ended in Apr. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenith Capital (TSXV:ZENI.P) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Zenith Capital Quick Ratio Related Terms
Thank you for viewing the detailed overview of Zenith Capital's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Zenith Capital Corporation is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical needs. The company is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for mCRPC in combination with androgen receptor inhibitor, XTANDI, with Astellas and Newsoara as collaborators; triple-negative breast cancer in combination with the PARP inhibitor TALZENNA with Pfizer as a collaborator; androgen receptor independent mCRPC in combination with immune checkpoint inhibitor KEYTRUDA and XTANDI with University of California, San Francisco as a collaborator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:ZENI.P has been successfully added to your 